EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response

Sophie R Sayers, Vesela S Gesheva, Jithu J Varghese, Rebecca Beavil, Min Zhao, Yee Cheah, David Hopkins, Nicholas H F Fine, Annie Hasib, David J Hodson, Paul W Caton iD

Endocrinology · 26.05.2026 · 167 (7)

DOI: 10.1210/endocr/bqag061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, online erschienen am 11.06.2026. Verfasst von Sophie R Sayers und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Obesity Theme, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 1UL, UK. Hauptthemen laut MEDLINE: Glucagon-Secreting Cells, Glucagon. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EFSD/Lilly European Diabetes Research Program, Diabetes UK, DRWF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Loss of functional beta-cell mass, coupled with alpha-cell dysfunction are key factors in pathophysiology of type 1 and type 2 diabetes. We have reported that extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is elevated in type 2 diabetes and that elevated eNAMPT levels promote beta-cell dysfunction.

Objective

To further investigate the effects of eNAMPT on beta-cell mass.

Methods

Islets isolated from CD1 and Ins1tm1.1(cre)Thor+/−; mTmGfl/− mice and human donors were exposed to eNAMPT (48-96 hours). CD1 mice were administered eNAMPT for 14 days. Alpha-, beta-, and delta-cell numbers were determined by glucagon, insulin, and somatostatin staining, respectively. Alpha-cell proliferation was assessed by bromodeoxyuridine (BrDU) uptake and Ki67 expression. Glucagon secretion was assessed via radioimmunoassay. Trans-differentiation was assessed by determining changes in presence of bi-hormonal cells in CD1/human islets and using Ins1tm1.1(cre)Thor+/−; mTmGfl/− islets to determine changes in GLU+/GFP+ and GLU+/TdT+ cells. Results eNAMPT treatment reduced beta-cell number and induced corresponding increases in alpha-cell number. Indicative of beta- to alpha-cell trans-differentiation eNAMPT induced increased presence of bi-hormonal INS+/GLU+ cells and PDX1+/GLU+ cells, and increased GLU+/GFP+ cells in Ins1tm1.1(cre)Thor+/−; mTmGfl/− mouse islets. In addition, eNAMPT induced alpha-cell proliferation, indicated by increased BrDU uptake. Despite marked elevation in alpha-cell number, alpha-cell function was compromised following eNAMPT exposure, indicated by impaired glucagon counterregulatory response (CCR) to low glucose levels.

Conclusion

This data supports a role for elevated eNAMPT levels in driving increased alpha-cell mass via a combination of beta- to alpha-cell trans-differentiation and alpha-cell proliferation. When combined with observed impaired CCR, these data have implications for both type 1 and type 2 diabetes pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Secreting CellsGlucagonAnimalsHumansMiceCell ProliferationInsulin-Secreting CellsMaleInsulinFemale

Stichwörter der Autor:innen

NAMPTalpha-cellsbeta-cellsglucagontype 1 diabetestype 2 diabetes

Substanzen

GlucagonInsulin

Autor:innen und Institutionen

  • Diabetes and Obesity Theme, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE1 1UL, UK.
  • Protein Production Facility, Randall Centre for Cell and Molecular Biophysics, King's College London, London SE1 1UL, UK.
  • Institute of Metabolism and Systems Research (IMSR), and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham B15 2TT, UK.
  • Department of Life Sciences, Manchester Metropolitan University, Manchester M15 6BH, UK.
  • Oxford Center for Diabetes, Endocrinology and Metabolism (OCDEM), NIHR Oxford Biomedical Research Centre, Churchill Hospital, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK.

ORCID-Profile: Paul W Caton

Förderung

  • EFSD/Lilly European Diabetes Research Program
  • Diabetes UK
  • DRWF
  • MRC
  • UKRI ERC Frontier Research Guarantee
  • SMF
  • European Research Council (ERC)
  • European Union's Horizon 2020

Zitieren

APA

Sayers, S. R., Gesheva, V. S., Varghese, J. J., Beavil, R., Zhao, M., Cheah, Y., Hopkins, D., Fine, N. H. F., Hasib, A., Hodson, D. J., & Caton, P. W. (2026). eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response. Endocrinology, 167(7). https://doi.org/10.1210/endocr/bqag061

Vancouver

Sayers SR, Gesheva VS, Varghese JJ, Beavil R, Zhao M, Cheah Y, et al. eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response. Endocrinology. 2026;167(7). doi:10.1210/endocr/bqag061

BibTeX
@article{Sayers2026,
  author = {Sayers, Sophie R and Gesheva, Vesela S and Varghese, Jithu J and Beavil, Rebecca and Zhao, Min and Cheah, Yee and Hopkins, David and Fine, Nicholas H F and Hasib, Annie and Hodson, David J and Caton, Paul W},
  title = {eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response},
  journal = {Endocrinology},
  year = {2026},
  volume = {167},
  number = {7},
  doi = {10.1210/endocr/bqag061}
}
Kostenlos starten →